BioNTech's colorectal cancer vaccine trial fails, shares drop 8%, Moderna down 6%, Pfizer steady.
BioNTech halted its Phase 2 trial for a colorectal cancer vaccine after a Data Safety Monitoring Board found no efficacy, causing its stock to fall 8%. This setback also pressured Moderna's shares, which dropped 6%, despite its recent melanoma vaccin...
